JPM | Free Full-Text | Mid-Regional Pro-Adrenomedullin and N-Terminal Pro-B-Type Natriuretic
Peptide Measurement: A Multimarker Approach to Diagnosis and Prognosis in Acute Heart …

Objectives This study sought to evaluate the efficacy and safety of sacubitril/valsartan
according to dose level achieved in the PIONEER-HF (Comparison of Sacubitril/Valsartan …

Background Initiation of evidence-based medications for patients with heart failure with
reduced ejection fraction (HFrEF) during hospitalization in contemporary practice is …

Epidemiologically, high-density lipoprotein (HDL) cholesterol levels have been inversely
associated to cardiovascular (CV) events, although a Mendelian Randomisation Study had …

Acute heart failure is a common and increasingly prevalent condition, affecting> 10 million
people annually. For those patients who survive to discharge, early readmissions and death …

Heart failure (HF) is one of the leading causes of morbidity and mortality worldwide.
Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor, has been approved for the …

Aims Sacubitril‐valsartan has been shown to have superior effects over angiotensin‐
converting enzyme inhibitors and angiotensin receptor blockers in patients with heart failure …

Renin-angiotensin-aldosterone system (RAAS) inhibition is a mainstay of the
pharmacological treatment of heart failure with reduced ejection fraction (HFrEF). In the last …

Dear Editor, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)(COVID-19) is
responsible for the current global pandemic. To date, no antivirals directed against the virus …

In this review, we discuss what is meant by “foundational” therapy for patients with heart
failure and reduced ejection fraction (HFrEF) and the evidence supporting the use of the five …